go back

Idecabtagene Vicleucel (Abecma) CAR-T Therapy

New Mexico rates for HCPCS Q2055

Idecabtagene vicleucel, up to 510 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

How much rates vary

Facilitymedian $870,964 · 10th to 90th $562,341 to $1,621,810Professionalmedian $707,946 · 10th to 90th $562,341 to $2,137,962
$1M$2Mfacility $870,964professional $707,946

Distribution of negotiated rates across all payers (price axis is log-scale). Each curve is scaled to its own total: facility and professional rates are different services, shown together to compare where they cluster. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$616,595.00
Median
$870,963.59
Typical High
$1,949,844.60
Aetna
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$707,945.78
Typical High
$2,137,962.09
United
Setting
Facility
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$933,254.30